Gynecologic, Ovarian, and Cervical Cancer

GYNECOLOGIC CANCER ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

Preclinical Work on Red Blood Cell-Based Therapies in HPV-Positive Solid Tumors Provides Rationale for Clinical Trials in Humans

A microfluidics platform for engineering activated antigen carrier immunotherapies from red blood cells showed promising preliminary results in a mouse model.
New Research Says There’s No Significant Link Between Talc and Ovarian Cancer, but Some Scientists Push Back Against the Study’s Data and Design

Some experts say the talc study’s data limitations weaken its impact in the field.
Multitumor “Exceptional Responder” Program in Australia Seeks to Gain Clinical Context

The first multitumor exceptional responder program in Australia is under way, adding to the growing worldwide effort to identify patient DNA changes and biomarkers of response.
Oncologists Debate Using Maintenance Bevacizumab in Stage IIIc Ovarian Cancer

In a recent paper published in the Journal of Clinical Oncology, the authors recommended using adjuvant and maintenance bevacizumab to treat a patient with stage IIIc ovarian cancer following an optimal (R0) resection.
Dual-Targeted CAR-T Therapies in Solid Tumors: Q&A With Dr Wayne Marasco

Dr Marasco explains that CAR-T therapies are really “cellular therapies that work by way of gene manipulation,” and describes a method through which he hopes CAR-T can produce durable, long-term treatments for solid tumors.

GYNECOLOGIC CANCER NEWS

Postsurgical Mutations Detected in Cell-Free DNA in Endometrial Cancer May Indicate Poor Prognosis

April 1, 2020

Women with BRCA 1/2 mutations have lower ovarian reserve and experience greater ovarian reserve loss

Potential Predictors of Cell Transformation in Normal Fallopian Tubes of Women With a Deleterious BRCA1 Mutation

April 1, 2020

Study results show that women who carry a BRCA1 mutation have a shorter reproductive lifespan than n

Real-World Data Show Low Rates of Somatic BRCA Mutation Testing in Ovarian Cancer

April 1, 2020

New SCOUT system offers a very accurate means of directing the removal of non-palpable breast lesion

Learning Curve Associated With Minimally Invasive Radical Hysterectomy May Be Steep, Study Finds

April 1, 2020

Further Refining Which Subgroups of Patients With Ovarian Cancer Benefit Most From Addition of Olaparib to Maintenance Therapy With Bevacizumab

March 31, 2020

Next post in Gynecologic Cancer

The indications for cervical cancer screening in asymptomatic average-risk women are described.

Copper Intrauterine Devices Tied to Lower Risk for Cervical Cancer